Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Type

Type

Guidance programme

Showing 1 to 17 of 17

TitleReference numberPublishedLast updated
Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resectionTA1043
Exagamglogene autotemcel for treating severe sickle cell disease in people 12 years and overTA1044
Durvalumab with etoposide and either carboplatin or cisplatin for untreated extensive-stage small-cell lung cancerTA1041
Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancerTA1042
Early and locally advanced breast cancer: diagnosis and managementNG101
Advanced breast cancer: diagnosis and treatmentCG81
Ganaxolone for treating seizures caused by CDKL5 deficiency disorder in people 2 years and overTA1033
Selpercatinib for advanced thyroid cancer with RET alterations after treatment with a targeted cancer drug in people 12 years and overTA1038
Selpercatinib for advanced thyroid cancer with RET alterations untreated with a targeted cancer drug in people 12 years and overTA1039
Olaparib for treating BRCA mutation-positive HER2-negative advanced breast cancer after chemotherapyTA1040
Artificial intelligence-derived software to analyse chest X-rays for suspected lung cancer in primary care referrals: early value assessmentHTE12
Ovarian cancerQS18
Pembrolizumab for adjuvant treatment of resected non-small-cell lung cancerTA1037
Elacestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer with an ESR1 mutation after endocrine treatmentTA1036
Intravascular lithotripsy to treat calcified coronary arteries during percutaneous coronary interventionIPG802
Digital technologies to support self-management of COPD: early value assessmentHTE19
Tobacco: preventing uptake, promoting quitting and treating dependenceNG209

Results per page

  1. 10
  2. 25
  3. 50
  4. All